Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase

Details Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase

2009-05-28

2011-11-01

Steadman, David J (Department: 1656)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Chemical analysis

C703S011000, C435S025000, C435S007210

Reexamination Certificate

active

08050873

ABSTRACT:
The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.

REFERENCES:
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 6020350 (2000-02-01), Weidmann et al.
patent: 6566088 (2003-05-01), McKnight et al.
patent: 6589758 (2003-07-01), Zhu
patent: 7183287 (2007-02-01), Durley
patent: 2002/0192737 (2002-12-01), Kaelin, Jr. et al.
patent: 2003/0153503 (2003-08-01), Klaus et al.
patent: 2003/0176317 (2003-09-01), Guenzler-Pukall et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: 2005/0143402 (2005-06-01), Cheetham et al.
patent: 2006/0276477 (2006-12-01), Klaus et al.
patent: 2007/0020684 (2007-01-01), Bledsoe et al.
patent: 2007/0154482 (2007-07-01), Sukhatme et al.
patent: 2007/0213335 (2007-09-01), Fitch et al.
patent: 2007/0299086 (2007-12-01), Kawamoto et al.
patent: 2008/0124740 (2008-05-01), Evdokimov et al.
patent: 2008/0213404 (2008-09-01), Johnson et al.
patent: 2009/0082357 (2009-03-01), Fitch et al.
patent: WO 97/41103 (1997-11-01), None
patent: WO 02/074980 (2002-09-01), None
patent: WO 02/074981 (2002-09-01), None
patent: WO 03/028663 (2003-04-01), None
patent: WO 2004/035812 (2004-04-01), None
patent: WO 2005/118836 (2005-12-01), None
patent: WO 2006/114213 (2006-11-01), None
patent: WO 2007/038571 (2007-04-01), None
patent: WO 2007/047194 (2007-04-01), None
patent: WO 2007/070359 (2007-06-01), None
patent: WO 2007/082899 (2007-07-01), None
patent: WO 2007/103905 (2007-09-01), None
patent: WO 2007/136990 (2007-11-01), None
patent: WO 2007/150011 (2007-12-01), None
patent: WO 2008/089051 (2008-07-01), None
patent: WO 2008/089052 (2008-07-01), None
patent: WO 2008/130508 (2008-10-01), None
patent: WO 2008/130527 (2008-10-01), None
patent: WO 2008/137060 (2008-11-01), None
patent: WO 2008/144266 (2008-11-01), None
patent: WO 2009/019656 (2009-02-01), None
patent: WO 2009/037570 (2009-03-01), None
patent: WO 2009/039321 (2009-03-01), None
patent: WO 2009/039323 (2009-03-01), None
patent: WO 2009/043093 (2009-04-01), None
patent: WO 2009/049112 (2009-04-01), None
patent: WO 2009/067790 (2009-06-01), None
patent: WO 2009/070644 (2009-06-01), None
patent: WO 2009/073497 (2009-06-01), None
patent: WO 2009/073669 (2009-06-01), None
patent: WO 2009/086044 (2009-07-01), None
patent: WO 2009/086592 (2009-07-01), None
patent: WO 2009/089547 (2009-07-01), None
Flower, “Drug Design, Cutting Edge Approaches,” Royal Society of Chemistry, Cambridge, UK, 2002.
Brucz, K., “HIF Prolyl 4-Hydroxylase (PHD) Activity and Structure Analysis: Blueprints For Development of Specific Substrate Inhibitors”, Dissertation, University of New York at Buffalo, 2005.
Bartlett et al., “Molecular Recognition in Chemical and Biological Problems,”Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).
Böhm, “The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,”J. Computer-Aided Molecular Design,6:61-78 (1992).
Bussolino, “Molecular Mechanisms of Blood Vessel Formation,”Trends Biochem. Sci.,22(7):251-256 (1997).
Cunliffe et al., “Novel Inhibitors of Prolyl 4-Hydroxylase 3 Inhibition by the Substrate AnalogueN-Oxaloglycine and Its Derivatives,”J. Med. Chem.35:2652-2658 (1992).
Elson et al., “Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1α,”Genes&Dev., 15:2520-2532 (2001).
Flower, “Modelling G-protein-coupled receptors for drug design,”Biochimica et Biophysica Acta, 1422:207-234 (1999).
Folkman et al., “Tumor Angiogenesis,”The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).
Franklin et al., “Approaches to the Design of Anti-Fibrotic Drugs,”Biochem Soc Trans., 19(4):812-5 (Nov. 1991).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J. Med. Chem., 28(7):849-857 (1985).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins: Structure, Function, and Genetics, 8:195-202 (1990).
Jones et al., “Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,”J. Mol. Biol., 245:43-53 (1995).
Kaelin, “Proline Hydroxylation and Gene Expression,”Annu. Rev. Biochem., 74:115-125 (2005).
Krantz, “Erythropoietin,”Blood, 77:419-434 (1991).
Kuntz et al., “A Geometric Approach to Macromolecule—Ligand Interactions,”J. Mol. Biol., 161:269-288 (1982).
Lee et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,”JBC, 278:7558-7563 (2003).
Li et al., “PR39, A Peptide Regulator of Angiogenesis,”Nat Med., 6(1):49-55 (2000).
Mancini et al., “Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,”Circulation, 107:294-299 (2003).
McDonough et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),”PNAS, 103(26):9814-9819 (2006).
Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,”Proteins: Structure, Function and Genetics, 11:29-34 (1991).
Nguyen et al., “Cellular Interactions in Vascular Growth and Differentiation,”Int. Review of Cytology, 204:1-48 (2001).
Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,”Tetrahedron, 47(43):8985-8990 (1991).
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”Cell, 79:315-328 (1994).
O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,”Cell, 88:277-285 (1997).
Peyssonnaux et al.,“HIF-1α Expression Regulates the Bactericidal Capacity of Phagocytes,”J. Clinical Invest., 115(7):1806-1815 (Jul. 2005).
Schoneberg et al., “Structural Basis of G Protein-Coupled Receptor Function,”Molecular and Cellular Endocrinology, 151:181-193 (1999).
Semenza et al., “Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,”J. Biol. Chem., 269:23757-23763 (1994).
Semenza, “Regulation of Erythropoietin Production: New Insights into Molecular Mechanisms of Oxygen Homeostasis,”Hematol. Oncol. Clin. North Am., 8:863-884 (1994).
Semenza, “Signal Transduction to Hypoxia-inducible Factor 1,”Biocehm Pharmacol, 64:993-998 (2002).
Sexton, “Recent advances in our understanding of peptide hormone receptors and RAMPS,”Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).
Sheehan, “3-Hydroxypicolinic Acid and Some of its Derivatives,”J. Organic Chemistry31(3):636-638 (1996).
Teicher et al., “Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,”Int. J. Cancer, 57:920-925 (1994).
Vincent et al., “Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1α/VP16 Hybrid Transcription Factor,”Circulation, 102:2255-2261 (2000).
Warnecke et al., “Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,”FASEB Journal, 17:1186-1188 (2003).
Wax et al., “SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,”Lab. Invest., 74(4

Affiliated with

Also associated with

Rating

Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4275089